Amitiza for IBS Constipation

Amitiza (lubiprostone) is a medication that is FDA-approved for the treatment of chronic idiopathic constipation (CIC) in adults and constipation-predominant IBS (IBS-C) in women over the age of 18. Amitiza is an oral medication that has a laxative effect.

Young woman holding painful abdomen on sofa

BJI / Lane Oatey / Getty Images

How It Works

Amitiza stimulates the release of fluids into the lining of the intestines. It is thought that this increased fluid secretion softens the stool and decreases stool transit time, thus relieving the symptoms of constipation. Amitiza's effects are thought to remain almost exclusively within the intestinal tract.

The American College of Gastroenterology in its 2014 research review, reports strong research support for the effectiveness of Amitiza in relieving constipation. Amitiza has been shown to:

  • Increase stool frequency
  • Produce more consistent, well-formed stools
  • Reduce straining and incomplete bowel evacuation
  • Reduce abdominal pain and discomfort

Who Shouldn't Take Amitiza

You should not take Amitiza if you are experiencing any symptoms of diarrhea or a bowel obstruction. Women who are breastfeeding should only take Amitiza under the supervision of their doctors. Amitiza has not been approved for use in children.

Side Effects

Amitiza is usually well-tolerated and serious side effects are rare. The following side effects have been reported:

Nausea associated with Amitiza is not a rare event: It's estimated that 19 to 29% of Amitiza users experience nausea. In order to reduce the risk of nausea, it is recommended that you take the medication with food.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  • Carter, N. & Scott L. "Lubiprostone: in constipation-predominant irritable bowel syndrome." Drugs 2009 69:1229-1237.

  • Ford, A., et.al. "American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation" American Journal of Gastroenterology 2014 109:S2-S26.

  • Gaman, A., Bucur, M. & Kuo, B. Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome. Therapeutic Advances in Gastroenterology 2009 2:169-181.

  • Lacy, B., Weiser, K. & Lee, R. The treatment of irritable bowel syndrome. Therapeutic Advances in Gastroenterology 2009 2:221 - 238.

  • Lacy, B. & Chey, W. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opinion on Pharmacotherapy 2009 10:143-152.

  • Chey, W., et.al. "Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation" Alimentary Pharmacology and Therapeutics 2012 35:587-599.
  • Johnston, J. et.al. “Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation” American Journal of Gastroenterology 2009 104:125-132.